Capital Group Investment Management PTE. LTD. Takes Position in Icon Plc $ICLR

Capital Group Investment Management PTE. LTD. bought a new stake in Icon Plc (NASDAQ:ICLR) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 6,478 shares of the medical research company’s stock, valued at approximately $1,180,000.

A number of other hedge funds have also recently bought and sold shares of the business. Toth Financial Advisory Corp bought a new position in Icon during the 4th quarter worth approximately $27,000. Ameriflex Group Inc. bought a new position in Icon during the 3rd quarter worth approximately $33,000. Johnson Financial Group Inc. bought a new position in Icon during the 3rd quarter worth approximately $71,000. Quadrant Capital Group LLC bought a new position in Icon during the 3rd quarter worth approximately $78,000. Finally, Geneos Wealth Management Inc. lifted its holdings in Icon by 11.5% during the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after buying an additional 56 shares during the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

Analyst Upgrades and Downgrades

ICLR has been the topic of several recent research reports. Citigroup raised their price target on Icon from $120.00 to $140.00 and gave the stock a “neutral” rating in a report on Friday, May 29th. Zacks Research downgraded Icon from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 25th. Jefferies Financial Group reiterated a “buy” rating and set a $165.00 price target on shares of Icon in a research report on Friday, May 29th. Bank of America reiterated an “outperform” rating on shares of Icon in a research report on Monday, June 1st. Finally, Barclays lifted their target price on Icon from $120.00 to $150.00 and gave the stock an “equal weight” rating in a report on Friday, May 29th. Eight research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Icon currently has an average rating of “Hold” and a consensus price target of $156.44.

Icon Stock Performance

Shares of Icon stock opened at $149.45 on Friday. The stock has a market cap of $12.07 billion, a PE ratio of 24.26, a price-to-earnings-growth ratio of 10.13 and a beta of 1.26. The business has a fifty day simple moving average of $117.51 and a 200-day simple moving average of $140.85. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.31. Icon Plc has a 12 month low of $66.57 and a 12 month high of $211.00.

Icon (NASDAQ:ICLR) last released its quarterly earnings data on Wednesday, May 27th. The medical research company reported $2.21 earnings per share (EPS) for the quarter. The firm had revenue of $2.11 billion during the quarter. Icon had a return on equity of 9.50% and a net margin of 5.98%.Icon has set its FY 2026 guidance at 10.000-11.000 EPS. On average, sell-side analysts anticipate that Icon Plc will post 9.74 EPS for the current fiscal year.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.